Tolga Tanguler Sells 1,598 Shares of Alnylam Pharmaceuticals Stock

Alnylam Pharmaceuticals, Inc. reported that its Executive Vice President, Tolga Tanguler, sold 1,598 shares of the company’s stock on March 2, 2023. The shares were sold at an average price of $327.65, resulting in a total transaction value of $523,584.70. Following this sale, Tanguler now owns 36,606 shares of Alnylam, which are valued at approximately $11,993,955.90. This sale represents a 4.18% reduction in his total ownership of the company’s stock.

The transaction was disclosed in a filing with the Securities and Exchange Commission (SEC), which can be accessed through the SEC’s official website. This disclosure is part of the regulatory requirements that ensure transparency in stock trading by company executives.

Alnylam Pharmaceuticals Stock Performance

As of Friday, the stock opened at $320.51. Alnylam Pharmaceuticals has a market capitalization of $42.51 billion. The company’s price-to-earnings ratio stands at 187.43, and its beta is 0.36, indicating lower volatility compared to the market. Recent trading data shows a fifty-day moving average of $353.84 and a two-hundred-day moving average of $415.74. The stock has experienced a fifty-two week low of $205.87 and a high of $495.55. Key financial metrics include a debt-to-equity ratio of 1.28, a quick ratio of 2.71, and a current ratio of 2.76.

Institutional Investment Activity

Recent trading activity indicates increased interest from institutional investors in Alnylam Pharmaceuticals. Groupama Asset Management raised its stake in the company by 160.4% in the third quarter, now holding 4,032,082 shares valued at $18,610,000 after acquiring an additional 2,483,697 shares. Norges Bank also entered the scene, purchasing a new stake worth approximately $895,816,000 in the fourth quarter.

Other significant movements include Arrowstreet Capital Limited Partnership, which increased its stake by an impressive 698.8% during the third quarter, now owning 1,355,609 shares valued at $618,158,000. Qube Research & Technologies Ltd and Holocene Advisors LP also made substantial investments in the company, with new positions worth approximately $369,943,000 and $194,616,000, respectively. Currently, institutional investors own approximately 92.97% of Alnylam’s stock.

Analyst Ratings and Market Outlook

Analysts have provided various ratings for Alnylam Pharmaceuticals in recent months. Royal Bank of Canada reduced its price target from $500.00 to $465.00, maintaining an “outperform” rating. Similarly, Morgan Stanley lowered its target price from $495.00 to $408.00 while assigning an “equal weight” rating. Truist Financial also adjusted its target from $535.00 to $530.00, reaffirming a “buy” rating.

Analysts from Wall Street Zen and Needham & Company LLC have provided a mix of ratings, with the former downgrading from a “strong-buy” to a “buy” and the latter lowering its target from $529.00 to $510.00. The consensus among analysts positions Alnylam Pharmaceuticals with an average rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals, Inc. is focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company aims to translate scientific discoveries into effective medicines, utilizing small interfering RNA (siRNA) technology to silence genes responsible for diseases. Alnylam has successfully brought multiple siRNA-based products to market, employing advanced delivery methods to target genetic drivers of various conditions.